Source comparison
TB-500 SubQ vs IM Injection Route Better: Comparison
Before selecting your administration route, understand how each approach aligns with protocol goals, injection frequency, and practical constraints. Systemic Bioavailability 85–92% (reaches therapeutic plasma levels in 3.2 hrs) 87–94% (reaches therapeutic plas
This comparison does not assign a generated winner or score.
- Before selecting your administration route, understand how each approach aligns with protocol goals, injection frequency, and practical constraints.
- Systemic Bioavailability
- 85–92% (reaches therapeutic plasma levels in 3.2 hrs)
- 87–94% (reaches therapeutic plasma levels in 2.8 hrs)
- Functionally equivalent. Difference is <30 minutes to Tmax
- Localized Tissue Concentration
- Baseline. No acute bolus effect beyond injection site
- 3–5× higher tissue concentration at injection site for first 60–90 min
- IM may offer transient advantage for acute injury protocols targeting specific muscle groups
- Injection Comfort & Soreness
- Minimal. Mild stinging, no residual soreness
- Moderate. 24–48 hr muscle tenderness, especially at >2 mg/mL concentrations
- SubQ is better tolerated for protocols requiring frequent administration
- Maximum Volume Per Site
- 1.5 mL (split dose if exceeding)
- 3 mL (vastus lateralis), 2 mL (deltoid)
- IM allows higher-volume single injections
- Needle Specifications
- 28–31 gauge, 0.5-inch (insulin syringe)
- 23–25 gauge, 1–1.5 inch
- SubQ uses smaller, more comfortable needles
- Injection Technique Complexity
- Simple. 90° angle, pinch skin, inject
- Moderate. Z-track method recommended to prevent leakage
- SubQ has lower technical barrier for self-administration